Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and TNF-alpha-antagonists, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.

Abstract: An exemplary center housing for a turbocharger includes a lubricant control valve that includes a stem seated at least partially in the center housing where the stem has one or more orifices for controlling lubricant flow. The exemplary center housing also includes a lubricant filter positioned adjacent the stem of the lubricant control valve. The lubricant filter is optionally replaceable, for example, being accessible by removal of the stem from the center housing. Various other exemplary devices, assemblies, systems, methods, etc., are also disclosed.

Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and pegsunercept, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and TACE (TNF alpha converting enzyme) inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: A turbocharger includes compressor and/or turbine end housing(s) and removable compressor and/or turbine shroud portion(s) configured in relation to the compressor and/or turbine wheel(s) such that either or both of the wheels can be removed, after removal of the respective shroud portion(s), without having to remove the respective end housing(s). Additionally or alternatively, a turbocharger includes removable and replaceable compressor and/or turbine seal(s) supported by removable compressor and/or turbine seal plate(s).

Abstract: An exemplary center housing for a turbocharger includes a filter well for receiving a lubricant filter unit. An exemplary filter unit, for attachment to a center housing of a turbocharger, includes an attachment mechanism to attach the filter unit to the center housing, a filter for filtering lubricant and a lubricant flow path where the lubricant flow path commences at a peripheral surface of the filter unit, passes through the filter and ends at a bore surface of the filter unit. Various other exemplary devices, assemblies, systems, methods, etc., are also disclosed.

Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4 are each independently H, NO2, CF3, SCF3, CN, halo, OH, OR6, NH2, NHR6, NR6R7, N+R6R7R8, COOH, COOR6, CONH2, CONHR6, CONR6R7, COH, COR6, SR6, SOR6, SO2R6, SO2OH, SO2OR6, SO2NH2, SO2NHR6, SO2NR6R7, alkyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl, with the proviso that at least one of R1, R2, R3, and R4 is other than H; or R1 and R2, R2 and R3, or R3 and R4, may together form part of a fused or unfused saturated or unsaturated ring system, optionally containing up to two heteroatoms selected from N, O, and S; R5 is OH, OR9, CN, CONH2, CONHNH2, CONHOH, CONHR9, CONR9R10, NH2, NHR9, or NR9R10; each R6, R7 and R8 is independently hydrocarbyl, or two of R6, R7 and R8 together form part of a saturated or unsaturated ring system, optionally containing up to two heteroatoms selected from N, O, and S; each R9 and R10 is independently hydrocarbyl, or R9 and R10 to

Abstract: The present invention relates to the use of 2-substituted 4-heteroaryl-pyrimidines and related compounds in the treatment of viral disorders.

Abstract: The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N—R5, and the other is C—R6; “a” is a single bond; “b”, “c”, “d”, “e” and “f” are single or double bonds so as to form a heteroaryl ring; R1 is is R7 with the proviso that R1 is other than H or Me; or (B) one of X and Y is S, and the other is NH or N—R5; “a” and “d” are each double bonds; “b”, “c”, “e” and “f” are each single bonds; R1 is oxo; and R2, R3, R4, R5, and R6 are each independently H or R7; R7 is a group (CH2)n—R8, wherein n is 0, 1, 2, 3 or 4 and wherein R8 is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF3, NO2, CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH2, NH-alkyl, NH-aryl, N(alkyl)2, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH2, CONH-alkyl, CON(alkyl)2, CONH-aryl, CONH-heteroaryl

Abstract: The present invention relates to substituted pyrimidines of formula I, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders and/or viral disorders.

Abstract: The present invention relates to novel pharmaceutical compositions based on fluorene carboxylic acid ester derived anticholinergics of formula 1 and soluble TNF receptor fusion proteins, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: The present invention relates to novel pharmaceutical compositions based on benzilic acid ester derived anticholinergics of formula 1 and soluble TNF receptor fusion proteins, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: The present invention relates to novel pharmaceutical compositions based on new anticholinergics and EGFR kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: The invention relates to the use of pteridines for the treatment of inflammatory and obstructive respiratory complaints, preferably asthma or COPD, as well as pharmaceutical compositions containing these compounds.

Abstract: The present invention relates to novel pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: The invention relates to the use of pyrimido[5,4-d]pyrimidines for the treatment of inflammatory and obstructive respiratory complaints, preferably asthma or COPD, as well as pharmaceutical compositions which contain these compounds.

Abstract: The present invention relates to novel pharmaceutical compositions based on a scopineester of formula 1 wherein X? has the meanings specified in the description and claims and one ore more, preferably one nicotinamide derivative, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: A pharmaceutical composition comprising an anticholinergic and at least one additional active ingredient selected from among corticosteroids, dopamine agonistes, PDE-IV inhibitors, NK1-antagonists, endothelin antagonists, antihistamines, and EGFR-kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.